exv4w3






Exhibit 4.3




Dated December 21, 2010




GLAXOSMITHKLINE LLC




and




MONCEF SLAOUI




SERVICE AGREEMENT




 









 




This Amended and Restated Agreement is made on December 21, 2010 between:





	(1)	 	GLAXOSMITHKLINE LLC whose trading office is at One Franklin Plaza, Philadelphia, Pennsylvania
19102, USA (the “Company”); and
	 
	(2)	 	MONCEF SLAOUI (the “Executive”).
	 
	1	 	Interpretation
	 
	1.1	 	In this Agreement (and any schedules to it)
	 
	 	 	“Accrued Obligations” means:
	 
	1.1.1	 	the Executive’s full salary under this Agreement through to the end of the month
in which the Termination Date occurs at the rate in effect on the Termination Date and the
reimbursement (in accordance with Group Policy) of any expenses incurred by the Executive
prior to the Termination Date;
	 
	1.1.2	 	any unpaid bonus pertaining to the previous financial year and the product of any
target bonus for the financial year in which the Termination Date occurs and a fraction, the
numerator of which is the number of days in the Company’s current financial year up to the
Termination Date and the denominator of which is 365, paid as soon as practicable following
the termination date
	 
	1.1.3	 	any remuneration previously deferred by the Executive (together with any accrued
interest) and not yet paid by the Company including payment for any accrued holiday not taken
by the Executive, in each case paid in accordance with the applicable plan, policy or program
of the Company; and
	 
	1.1.4	 	any other benefits to which the Executive is entitled, as determined in accordance
with the applicable plans and policies of the Company;
	 
	 	 	““Agreement” means this amended and restated employment agreement, which as of the date
hereof supersedes and replaces that employment agreement between the Company and the
Executive, dated 16 May 2006.
	 
	 	 	“Board” means the board of directors of the Company from time to time or any person or
committee nominated by that board as its representative for the purposes of this Agreement;
	 
	 	 	“Chief Executive Officer” means the Chief Executive Officer of GSK plc from time to time;
	 
	 	 	“Employment” means the employment governed by this Agreement;
	 
	 	 	“Group” means the Company and any other Company controlling, controlled by or under the
direct or indirect common control of the Company, including, without limitation, GSK plc and
any of its subsidiaries from time to time;
	 
	 	 	“Group Company” means a member of the Group and “Group Companies” will be interpreted
accordingly;
	 
	 	 	“GSK Board” means the board of directors of GSK plc from time to time or any person or
committee nominated by that board as its representative for the purposes of this Agreement;
	 
	 	 	“GSK plc” means GlaxoSmithKline plc




 - 2 - 









 






	 	 	“Termination Date” means the date on which the Employment terminates pursuant to this
Agreement;
	 
	1.2	 	References to any statutory provisions include any modifications or re-enactments
of those provisions.
	 
	1.3	 	In this Agreement terms used in the context of the GlaxoSmithKline Share Option
Plan and Performance Share Plan shall have the meaning ascribed to them in such plans.
	 
	2	 	Employment
	 
	 	 	The Company confirms the employment of the Executive, and the Executive confirms his
employment with the Company, on the terms and conditions set out in this Agreement.
	 
	3	 	Termination by Notice
	 
	3.1	 	The Executive’s continuous employment began on 3 October 1988.
	 
	3.2	 	The Employment under the terms of this Agreement shall be deemed to have commenced
on 1 June 2006 and the Employment shall continue until:






	 	(i)	 	the Employment is otherwise terminated in accordance with this Agreement; or
	 
	 	(ii)	 	not less than 12 calendar months’ notice in writing is given by the Company to
the Executive; or
	 
	 	(iii)	 	not less than 12 calendar months’ notice in writing is given by the Executive
to the Company; or
	 
	 	(iv)	 	the first day of the month coincident with or next following the date on which
the Executive attains age 60. In the event that this Agreement shall terminate pursuant
to this Clause 3.2(iv), then the Executive shall thereafter be deemed an Employee at
will and shall be entitled only to payment of Accrued Obligations.






	3.3	 	Subject to Section 3.4, the Company may, in its absolute discretion, lawfully
terminate the employment of the Executive at any time by paying to the Executive a sum equal
to his basic salary (excluding any other benefits) for the period this Agreement would
otherwise continue. For this purpose, basic salary shall be the basic annual salary in effect
at the date of termination of the employment.
	 
	3.4	 	If the Company chooses to enforce the restriction in Section 16.2.1 to prevent the
Executive from engaging in any business activities for any part of the Restricted Period
following the Termination Date, then in addition to paying the sum provided in Section 3.3,
the Company must also pay to the Executive a sum equal to his bonus (calculated on a time
pro-rated basis and on the assumption of on-target bonus performance) for the above part of
the Restricted Period.
	 
	4	 	Duties and Responsibilities
	 
	4.1	 	The Executive is the Chairman, R&D of GSK plc. The Executive will be compensated
at grade 0. The Executive shall have such powers and duties as are from time to time given to
him by the Chief Executive Officer or, if different, the person to whom the Executive reports,
consistent with the Employment and this Agreement.





 - 3 - 









 






	4.2	 	During the Employment, the Executive shall devote his full business time and
energies to the business and affairs of the Company and GSK plc, consistent with any other
duties and responsibilities he may have to any Group Companies. The Executive’s time shall be
allocated among the Group Companies in accordance with the Executive’s reasonable judgment and
dependent upon the level of his responsibilities to any other Group Company, subject to the
overall supervision and direction of the Chief Executive Officer or, if different, the person
to whom the Executive reports.
	 
	4.3	 	The Executive shall not, without the prior written consent of the GSK Board, accept
directorships, trusteeships and other appointments (other than of Group Companies) or carry on
or be engaged, concerned or interested either directly or indirectly in any other business or
activity. A list of the directorships and outside interests of the Executive approved by the
GSK Board as at the date of this Agreement is attached as Appendix 1 to this Agreement. Any
fees earned by the Executive in respect of such authorised activities may be retained by the
Executive.
	 
	4.4	 	The location of the Executive’s activities shall be in Philadelphia, Pennsylvania,
but subject to the overall supervision and direction of the Chief Executive Officer, and to
perform properly his duties, he may be required to undertake reasonable travel elsewhere in
the world. The Executive is required to reside at a location convenient to the Company’s
offices in Philadelphia, Pennsylvania (or such other location as the Company may determine)
during the Employment.
	 
	5	 	Salary, etc.
	 
	5.1	 	In consideration of the services to be rendered by the Executive under this
Agreement the Executive shall be paid a salary at the rate of $975,000 per annum payable in
accordance with the Company’s pay practices for its executives from time to time in force (but
not less frequently than calendar monthly). The salary will be credited to the Executive’s
bank account notified to the Company for the purpose. Salary shall be reviewed annually in
accordance with the Company’s normal administrative practices for its executives and may be
increased (but not reduced) by the Company by such amount (if any) as it shall think fit.
	 
	5.2	 	The Executive shall be entitled, subject to Section 6.4, to participate






	 	(i)	 	in all such cash bonus plans and programmes as are made available from time to
time for executives of the Company generally of the same grade in the relevant
jurisdiction in accordance with the Company’s policy (or GSK plc’s policy, as
applicable); and
	 
	 	(ii)	 	in respect of the salary provided by Section 5.1, in such incentive programmes
as are made available from time to time for executives of the Company and/or GSK plc
generally who are of the same grade in the relevant jurisdiction,






	 	 	in each case, subject to the terms and conditions of such bonus plans and programmes from
time to time in force. Any grant of share options or awards of performance shares under such
plans and programmes shall be granted subject to performance conditions as determined by the
GSK Board. The Executive’s future participation in certain of these plans and programmes may
be affected if the Executive does not satisfy the Share Ownership Requirements (as amended
from time to time). It is agreed that in the event of the Executive retiring from the
Company, the Executive will retain the relevant number of shares (as set out in the Share
Ownership Requirements) until at least one year after the earlier of (i) the date upon which
the Executive retires from the Company in accordance




 - 4 - 









 






	 	 	with the terms of any Company policy that may be in force from time to time, or (ii) the
date on which the Executive’s employment is terminated pursuant to Section 3.2(iv) of this
Agreement.






	5.3	 	The Executive’s salary under Section 5.1 of this Agreement shall be inclusive of
any fees or other remuneration to which the Executive may be entitled or receives as a
Director, alternate Director, specialist adviser, consultant or by virtue of any other office
or appointment in any Group Company. The Executive shall account to the Company for all such
fees or other remuneration by paying over or procuring to be paid over the same to the
Company.






	5.4	 	GSK shall not be liable for any costs or expenses, including any costs or expenses
pertaining to travel undertaken by the Executive, incurred as a result of any activity or
participation in any role or capacity external to and unrelated to GSK or any Group Company.
It is agreed that the Executive will promptly reimburse GSK against any such costs that may be
incurred by GSK. Further, the Executive authorises the Company at any time to deduct from his
salary, or any other monies payable to him by the Company, all sums which he owes the Company.
If this is insufficient, the Company will require repayment of the balance.
	 
	6	 	Expenses and other Benefits
	 
	6.1	 	The Company shall promptly reimburse to the Executive all reasonable travel and
other out of pocket expenses properly incurred by him in the performance of his duties under
the Employment. The Executive will submit claims for expense reimbursement to the Company
regularly with appropriate supporting documentation.
	 
	6.2	 	The medical benefit arrangements for the Executive and his family are as set out in
the GlaxoSmithKline Executive Medical Plan (as amended from time to time). Details, including
eligibility criteria are set out in the TotalReward section on connectGSK.
	 
	6.3	 	The Company at its expense shall provide the Executive with other benefits provided
to executives of the Company of the same grade, and the Executive shall be entitled to
participate in all benefit plans, practices and policies as are made available by the Company
from time to time to its executives generally of the same grade subject to their terms and
conditions from time to time in force. A list of all plans and programmes currently in
operation is set out in Appendix 2. Details of the relevant plans and programmes are set out
in the TotalReward section on connectGSK.
	 
	6.4	 	GSK shall not be liable for any costs or expenses, including any costs or expenses
pertaining to travel undertaken by the Executive, incurred as a result of any activity or
participation in any role or capacity external to and unrelated to GSK or any Group Company.
It is agreed that the Executive will promptly reimburse GSK against any such costs that may be
incurred by GSK. Further, the Executive authorises the Company at any time to deduct from his
salary, or any other monies payable to him by the Company, all sums which he owes the Company.
If this is insufficient, the Company will require repayment of the balance.
	 
	6.5	 	The Company (and GSK plc, as applicable) reserves the absolute right and discretion
to amend, modify or terminate all such benefits, plans and programmes as are referred to in
Sections 5.2, 6.2, 6.3 and 8 at any time and for any reason.





 - 5 - 









 






	7	 	Vacation
	 
	 	 	In addition to all Company Holidays, the Executive shall be entitled to 30 days’
vacation in each year at full pay in accordance with Company policy from time to time in
force, which shall accrue rateably during the calendar year, to be taken at such times as
the business of the Company may permit. On termination of the Employment the Executive will
be entitled to be paid for any accrued vacation not taken and will reimburse the Company for
any vacation taken but not accrued.
	 
	 	 	Vacation which is not taken in the year in which it is accrued may be carried forward in
accordance with the Company’s rules on the banking of vacation outlined in its Vacation
Policy, as amended from time to time. Any vacation which is not carried forward in
accordance with these rules will be lost.
	 
	8	 	Pension and Life Insurance
	 
	 	 	The Executive shall be entitled to participate in the GlaxoSmithKline Cash Balance
Pension Plan and the GlaxoSmithKline Supplemental Pension Plan and any other retirement
plans or deferred compensation programmes made available by the Company to its senior
executives in the United States, including, without limitation, the GlaxoSmithKline
Retirement Savings Plan and the GlaxoSmithKline Executive Supplemental Savings Plan ,
subject to the terms and conditions of such programmes from time to time in force. Details
of such current plans and programmes are set out in the TotalReward section on connectGSK
and are subject to amendment or withdrawal at the Company’s discretion.
	 
	9	 	Sickness
	 
	9.1	 	The Executive shall comply with the Company’s sick pay rules from time to time in
force.
	 
	9.2	 	The Executive shall be entitled to participate in the Company’s short-term and
long-term disability plans or programmes in force from time to time.
	 
	9.3	 	The Company may require the Executive to have a medical examination every year (or
at such shorter intervals as they may agree between them), by a doctor approved by the
Company. The costs of such examinations shall be borne by the Company. The Executive shall
authorise such doctor to submit to the Director of Human Resources of the Company a copy of
the medical report or results of any tests prepared or obtained as a result of that
examination (which shall omit reference to any medical condition which in the doctor’s opinion
would not affect the Executive’s capability to perform his duties then or in the future).
	 
	10	 	Inventions and Copyright
	 
	 	 	The Company’s standard policy on inventions and copyright from time to time in force
shall apply to the Executive.
	 
	11	 	Confidentiality; Company Securities
	 
	11.1	 	Without prejudice to any other duty owed to the Company or to any Group Company,
the Executive shall not, except in the proper performance of his duties or as authorised by
the Board, during or after the Employment, use or disclose to any person any Confidential
Information obtained by him during the Employment.





 - 6 - 









 






	11.2	 	In the course of the Employment, the Executive is likely to obtain trade secrets
and confidential information belonging to or relating to Group Companies and other persons. He
will treat such information as if it falls within the terms of Section 11.1 and Section 11.1
will apply with any necessary amendments to such information. If requested to do so by the
Company, the Executive will enter into an agreement with other Group Companies and any other
persons in the same terms as Section 11.1 with any amendments necessary to give effect to this
provision.
	 
	11.3	 	For the purposes of this Agreement, the term “Confidential Information” shall
include, but not be limited to confidential commercial, financial and strategic data
pertaining to the Group and any other confidential information relating to the business or
affairs of the Group including, without limitation, any invention, trade secret, manufacturing
process or patent information. The term “Confidential Information” shall not include any
information:
	 
	11.3.1	 	which is or becomes generally available to the public, or
	 
	11.3.2	 	which is acquired by the Executive apart from his association with the Group
	 
	 	 	other than, in each case, as a result of disclosure by the Executive or by any person to
whom he has supplied information or by any person in breach of a duty of confidentiality.
	 
	 	 	In addition, the term “Confidential Information” shall not include any information which the
Executive is required to disclose by applicable law or regulation or by order of a court or
governmental body of competent jurisdiction, so long as the Executive gives the Chief
Executive Officer of the Company reasonable prior notice of such required disclosure.
	 
	11.4	 	During the Employment, the Executive shall be bound, in respect of transactions in
securities issued by any Group Company, by the Company’s and GSK plc’s policies from time to
time in effect on employee securities dealing. In particular, the Executive shall advise the
Company Secretary, CFO, CEO or Chairman of GSK plc before he or any member of his immediate
family seeks to trade in such securities and shall be bound by any directions given by the
Company Secretary, CFO, CEO or Chairman.
	 
	12	 	General Termination Provisions
	 
	12.1	 	On the termination of the Employment for whatever reason, or at any other time
when requested to do so by the Company, the Executive, upon receipt of written request from
the Company, shall promptly






	 	(i)	 	deliver up to the Company any property belonging to the Company or any other
Group Company which may be in his possession or under his control including
Confidential Information, lists of customers, correspondence, documents and other
property. The Executive will not retain any copies of any materials or other
information. The Company shall promptly return to the Executive and permit him to
remove from the premises of the Company and any other Group Company, any property,
personal records, files, etc. belonging to the Executive; and
	 
	 	(ii)	 	resign on request by the Company or the GSK Board (if he has not already done
so) from all offices held by him in the Company and any other Group Company (except for
any he is entitled to retain under any separate agreement with any Group Company),
failing which the Executive irrevocably authorises the Company or GSK plc to appoint an
officer of the Company or GSK plc to execute all documents on his behalf and do all
things necessary to effect such resignations;




 - 7 - 









 






	 	 	 	PROVIDED, however, that any such resignations pursuant to this Section 12.1(ii)
shall be without prejudice to the Executive’s rights under this Agreement.






	12.2	 	Any termination of the Employment shall be without prejudice to the Executive’s
and the Company’s continuing obligations under this Agreement.
	 
	12.3	 	Upon the termination of the Executive’s employment for whatever reason, the
Executive shall immediately repay all outstanding debts or loans due to the Company or any
Group Company and the Company is hereby authorised to deduct from any payment of wages any sum
in repayment of all or any part of such debts or loans.
	 
	12.4	 	The terms of the US GSK Severance Policy as in force from time to time, shall not
apply to the Executive.
	 
	13	 	Termination due to Death or Disability
	 
	13.1	 	In the event of the Executive’s death the Employment will terminate automatically
on the date of his death, which shall be the Termination Date for the purposes of this
Agreement. His duly qualified executor shall be entitled to receive the Accrued Obligations.
	 
	13.2	 	The Company may elect to terminate the Employment immediately without notice or
payment in lieu of notice by serving written notice (“Termination Notice for Disability”), if
an independent physician selected by the Company has certified in writing that, by reason of a
physical or mental illness or other condition of the Executive, the Executive is unlikely to
be able to resume performance of duties under the Employment for the foreseeable future. The
Employment will terminate on the Termination Date specified in the Termination Notice for
Disability. Provided that the Company shall not be entitled to terminate the employment by
reason of physical or mental illness or other condition if this would lead to the Executive
becoming dis-entitled to benefits under the Company’s or GSK plc’s permanent health insurance
plan.
	 
	13.3	 	In the event the Company delivers a Termination Notice for Disability, the
Executive shall immediately be relieved from all offices, appointments and responsibilities
that he may then hold under the Employment and be relieved of any duty to work for or serve
the Company or any Group Company. The Executive shall be entitled only to the Accrued
Obligations, together with such rights as are provided for in the applicable benefits plan(s)
in which the Executive participates.
	 
	14	 	Termination for Cause
	 
	14.1	 	The Company shall be entitled to terminate the Employment immediately without
notice or payment in lieu of notice for Cause (as defined in this Section 14) by serving
written notice (“Notice of Termination for Cause”).
	 
	14.2	 	“Cause” shall mean:
	 
	14.2.1	 	the Executive is convicted of any criminal offence which in the reasonable
opinion of the Chairman of GSK plc or the GSK Board affects the Executive’s position as
Chairman R&D of GSK plc (other than a motoring offence for which no custodial sentence is
given to him) ; or
	 
	14.2.2	 	the Executive, in carrying out his duties under the Employment, is guilty of
gross neglect or gross misconduct; or





 - 8 - 









 






	14.2.3	 	the Executive shall become personally bankrupt or insolvent; or
	 
	14.2.4	 	the Executive shall be or become prohibited by law from being a director; or
	 
	14.2.5	 	the Executive commits a material breach of any term of this Agreement.
	 
	14.3	 	Any delay or forbearance by the Company in exercising any right of termination
shall not constitute a waiver of it.
	 
	14.4	 	In the event that the Employment is terminated for Cause, the Employment shall
terminate upon the date on which the Board serves Notice of Termination for Cause and the
Executive shall be entitled only to payment of all previously accrued and unpaid salary then
due and owing under this Agreement, up to the date of termination including reimbursement for
expenses previously incurred and, save for the provisions of this Section 14.4, the Executive
will have no claim for damages or any other remedy against the Company or any Group Company.
	 
	15	 	Termination by Notice
	 
	15.1	 	Subject to Sections 13 and 14 of this Agreement, the Employment under the terms of
this Agreement shall terminate on the occurrence of either:
	 
	15.1.1	 	The election of the Company, upon not less than 12 months notice in writing by
the Company to the Executive in accordance with Section 3.2(ii); or
	 
	15.1.2	 	The election of the Executive, upon not less than 12 months notice in writing by
the Executive to the Company in accordance with Section 3.2(iii).
	 
	 	 	Notwithstanding any other provision of this Agreement to the contrary, if, following
delivery of the notice as required under Section 3.2(ii) or 3.2(iii), the Executive abandons
his employment with the Company prior to expiration of the 12 month notice period, the
Executive shall be entitled to receive only those payments set forth in Section 15.3 of this
Agreement.
	 
	15.2	 	In the event the Employment terminates pursuant to Section 15.1.1, subject to
Section 15.2.1, the Executive shall be entitled to receive the Accrued Obligations as soon as
practicable following the Termination Date coinciding with the expiration of the 12 month
notice period. Alternatively, the Company may, in its absolute discretion, lawfully terminate
the Employment immediately upon delivery of the written notice set forth in Section 3.2(ii)
and paying the Executive a cash payment equal to 100% of his annual base salary (as in effect
immediately prior to the Termination Date), payable in a lump sum as soon as practicable
following the Termination Date.
	 
	15.2.1	 	Where Section 15.2 applies, if the Company chooses to enforce the restriction
contained in Section 16.2.1 to prevent the Executive from engaging in any business activities
for any part of the Restricted Period following the Termination Date, then the cash payment in
Section 15.2 shall include also the Executive’s bonus (calculated on a time pro-rated basis
and on the assumption of on-target bonus performance).
	 
	15.3	 	In the event the Employment terminates pursuant to Section 15.1.2, or if the
Executive abandons the Employment following delivery of the notice set forth in Section
3.2(ii) or 3.2(iii) but prior to expiration of the 12 month notice period, the Executive shall
be entitled only to payment of all previously accrued and unpaid salary then due and owing
under this Agreement, up to the Termination Date, any unpaid bonus pertaining to the previous
financial year, and reimbursement for expenses previously incurred and, save for the




 - 9 - 









 






	 	 	provisions of this Section 15.3, the Executive will have no claim for damages or any other
remedy against the Company or any Group Company. The amounts described in this Section 15.3
shall be paid as soon as practicable following the Termination Date.






	15.4	 	The Company and the Executive agree that if the Company shall fully perform, when
due, all its obligations under this Section 15, such performance shall be in full and final
settlement of all and any claims or rights of action which the Executive might have against
the Company, or any Group Company arising out of this Agreement or its termination or
otherwise howsoever relating to the Employment.
	 
	15.5	 	A removal by the Company of the Executive from his current position which results
in a demotion to a position with less responsibility than his current position, or a change in
reporting relationships which results in the Executive no longer reporting directly to the GSK
Board, or any successor board, will be deemed to be a termination by the Company on notice
pursuant to Section 15 of this Agreement.
	 
	16	 	Restrictions during and after Termination of Employment
	 
	16.1	 	In this Section:
	 
	 	 	“Restricted Business” means the businesses of the Company or any Group Company at the
Termination Date with which the Executive was involved to a material extent during the last
12 months of the Employment.
	 
	 	 	“Restricted Period” means any period during which the Executive is employed by the Company
and the period of 12 months commencing on the Termination Date.
	 
	16.2	 	The Executive is likely to obtain trade secrets and confidential information and
personal knowledge of and influence over customers, clients and employees of the Company, GSK
plc and its Group Companies during the course of the Employment. To protect these interests,
the Executive agrees with the Company and GSK plc that the Executive will be bound by the
following covenants:
	 
	16.2.1	 	During the Restricted Period he will not be engaged in (except as the holder,
directly or indirectly, of less than 5 per cent of the shares) any business which is or is
about to be in competition with the Restricted Business.
	 
	16.2.2	 	During the Restricted Period the Executive will not, canvass or solicit in
competition with the Company, or any Group Company any person who was during the last 12
months of the Employment a customer, or client of, or in the habit of dealing with, the
Company, or (as the case may be) any Group Company and in respect of which the Executive had
access to confidential information or with whose custom or business the Executive is or was
personally concerned, during that 12 month period with a view to providing goods or services
to that person in competition with any Restricted Business.
	 
	16.2.3	 	During the Restricted Period he will not, in the course of any business concern
which is in competition with the Restricted Business provide goods or services to or otherwise
have any dealings with any person who was during the last 12 months of the Employment a
customer, or client of, or in the habit of dealing with the Company, or any Group Company, and
in respect of which the Executive had access to confidential information or with whose custom
or business the Executive is or was personally concerned during that 12 month period.





 - 10 - 









 






	16.2.4	 	During the Restricted Period he will not, interfere or endeavour to interfere
with the continuance of the provision of goods or services to the Company, or any Group
Company, by any supplier which was a supplier of goods or services to the Company, or any
Group Company during the last 12 months of the Employment and with whom the Executive dealt to
a material extent during that period.
	 
	16.2.5	 	During the Restricted Period he will not entice or try to entice away from the
Company or any Group Company any person who is still employed by the Company or a Group
Company during the Restricted Period and is a senior employee, director or full time senior
consultant of such a company and with whom he worked closely in the last six months of the
Employment.
	 
	16.3	 	Each of the obligations imposed on the Executive by this Section 16 extend to him
acting not only on his own account but also on behalf of any other firm, company or other
person and shall apply whether he acts directly or indirectly.
	 
	16.4	 	Following the Termination Date, the Executive will not represent himself as being
in any way connected with the businesses of the Company, GSK plc or of any other Group Company
(except to the extent agreed in writing by such a company).
	 
	16.5	 	Any benefit given or deemed to be given by the Executive to any Group Company
under the terms of Section 16 is received and held on trust by the Company for the relevant
Group Company. The Executive will enter into appropriate restrictive covenants directly with
other Group Companies if asked to do so by the Company or GSK plc.
	 
	17	 	Reasonableness of Restrictions
	 
	17.1	 	Each of the obligations on the Executive contained in Section 16 constitutes a
separate and independent restriction on the Executive notwithstanding that they may be
contained in the same Section, paragraph or sentence.
	 
	17.2	 	Should the restrictions contained in Section 16 be found to be void but would be
valid if some part thereof were deleted or the period or radius of application reduced, then
such restriction shall apply with such modification as may be necessary to make it valid and
effective. In particular, the Executive agrees that the restrictions are reasonable and
necessary for the protection of the Company and the Group Companies.
	 
	17.3	 	If the Executive shall, during the Restricted Period, receive from any person,
firm or company, an offer to provide services in any capacity whatsoever, or to enter into
employment where acceptance of such offer, or the taking of such employment, might render him
in breach of the provisions of this Agreement, he shall promptly advise the offeror of the
existence of the restrictions set forth in Section 16 of this Agreement.
	 
	17.4	 	The Executive acknowledges that the Company may have no adequate remedy at law and
would be irreparably harmed if the Executive breaches or threatens to breach the provisions of
Section 16 above and, therefore, agrees that the Company shall be entitled to injunctive
relief to prevent any breach or threatened breach of Section 16 above, and to specific
performance of the terms of each such Section in addition to any other legal or equitable
remedy it may have. The Executive further agrees that he shall not, in any equity proceedings
involving him relating to the enforcement of Section 16 above raise the defence that the
Company has an adequate remedy at law. Nothing in this Agreement shall be construed as
prohibiting the Company from pursuing any other remedies at law or in equity that it may have.





 - 11 - 









 






	18	 	Severability
	 
	 	 	In the event that any provision or portion of this Agreement shall be determined to be
invalid or unenforceable for any reason, the remaining provisions or portions of this
Agreement shall be unaffected thereby and shall remain in full force and effect to the
fullest extent permitted by law.
	 
	19	 	Successors and Assigns
	 
	19.1	 	This Agreement shall be binding upon and inure to the benefit of the Company or
any corporation or other entity to which the Company may transfer all or substantially all of
its assets and business and to which the Company may assign this Agreement, in which case
“Company”, as used in this Agreement, shall mean such corporation or other entity. The
foregoing shall not relieve the Company of any of its obligations under Section 15 of this
Agreement. The rights of the Executive shall inure to the benefit of his heirs, executors,
administrators and other personal representatives.
	 
	19.2	 	The Executive may not assign this Agreement or any part of it, or any rights
thereunder or delegate any duties to be performed by him under it to anyone else.
	 
	20	 	Survivorship
	 
	 	 	To the extent contemplated by this Agreement, respective rights and obligations of the
parties set out in this Agreement shall survive any termination of this Agreement to the
extent necessary to the intended preservation of such rights and obligations.
	 
	21	 	Notices
	 
	 	 	Any notice (including any notice of termination of the Employment) required or
permitted to be given under this Agreement shall be in writing and shall be deemed to have
been given when delivered personally or sent by courier, duly addressed to the party
concerned at the address set out above or to such other address as the party may notify to
the other. Any notice delivered personally under this Section 21 shall be deemed given on
the date delivered and any notice sent by courier shall be deemed given on the date delivery
is recorded by such courier.
	 
	22	 	Entire Agreement
	 
	22.1	 	This Agreement supersedes any previous written or oral agreement between the
parties in relation to the matters dealt with in it. It contains the whole agreement between
the parties relating to the Employment at the date the agreement was entered into (except for
those terms implied by law which cannot be excluded by the agreement of the parties). The
Executive acknowledges that he has not been induced to enter into this Agreement by any
representation, warranty or undertaking not expressly incorporated into it.
	 
	22.2	 	Neither party’s rights or powers under this Agreement will be affected if:
	 
	22.2.1	 	one party delays in enforcing any provision of this Agreement; or
	 
	22.2.2	 	one party grants time to the other party.





 - 12 - 









 






	23	 	Amendment or Modification; Waiver
	 
	 	 	No provision of this Agreement may be amended or waived unless such amendment or waiver
is agreed to in writing, signed by the Executive and by a duly authorised officer of the
Company who shall supply the Executive with evidence of such authority.
	 
	24	 	Withholding
	 
	 	 	Anything to the contrary notwithstanding, all payments required to be made by the
Company under this Agreement to the Executive, or to his estate or beneficiaries, shall be
subject to withholding of such amounts relating to taxes as the Company may be required to
withhold pursuant to any applicable statute, law or regulation.
	 
	25	 	Indemnification and Insurance
	 
	25.1	 	The Company agrees that if the Executive is made a party or is threatened to be made a
party to any action, suit, proceeding or governmental or other investigation by reason of the
fact of the Employment or that he is or was a director, officer or employee of the Company or
is or was serving at the request of the Company as a director, officer, employee or agent of
another Group Company or entity except for any action instigated by the Company or the
Executive (a “Proceeding”), he shall be indemnified by the Company to the fullest extent
permitted by applicable law against all expenses, liabilities and losses reasonably incurred
or suffered by the Executive in connection with such a Proceeding (including any tax payable
by the Executive as a result of payments made by the Company pursuant to this indemnity),
including, without limitation, payment of expenses incurred in defending a Proceeding prior to
the final disposition of such Proceeding; PROVIDED, however, that written notice of such
Proceeding is given promptly to the Company by the Executive and the Company is permitted
(where appropriate) to participate in and assume the defence of such Proceeding. The
provisions of this Section 25 shall survive the termination of the Employment and shall be in
addition to any other rights to indemnification to which the Executive may from time to time
be entitled, whether under any applicable insurance policies or otherwise.
	 
	25.2	 	The Company will provide the Executive with Legal Expenses Insurance and Directors’ and
Officers’ Liability Insurance under the Company’s policy current from time to time in force
subject to such cover being available at reasonable commercial rates.
	 
	26	 	Collective Agreements — Disciplinary Rules and Procedures
	 
	 	 	There are no collective agreements which directly affect the terms and conditions set
out in this Agreement.
	 
	 	 	The Company’s harassment and bullying policies, disciplinary rules and procedures and
grievance procedures, as in force from time to time, shall apply to the Executive. The
Company reserves the right to leave out any or all of the stages of those rules and
procedures where it considers it appropriate to do so.
	 
	27	 	Data Protection
	 
	 	 	The Executive consents to the Company or any Group Company holding and processing both
electronically and manually the data it collects which relates to the Executive for the
purpose of the administration and management of its employees and its business and for




 - 13 - 









 






	 	 	compliance with applicable procedures, laws and regulations. The Executive also consents to
the transfer of such personal information to other offices the Company may have or to a
Group Company or to other third parties whether or not outside the United States for
administration purposes and other purposes in connection with the Executive’s employment
where it is necessary or desirable for the Company to do so.






	28	 	Section 409A
	 
	28.1	 	It is the intention of the parties to this Agreement that no payment or
entitlement pursuant to this Agreement will give rise to any adverse tax consequences to the
Executive under Section 409A of the Code and Department of Treasury regulations and other
interpretive guidance issued thereunder, including that issued after the date hereof. The
Agreement shall be interpreted to that end and, consistent with that objective and
notwithstanding any provision herein to the contrary, the Company may take any action it deems
necessary or desirable to amend any provision herein to avoid the application of or excise tax
under Section 409A, after giving the Executive reasonable notice and opportunity to comment.
Further, no effect shall be given to any provision herein in a manner that reasonably could be
expected to give rise to adverse tax consequences under Section 409A of the Code.
	 
	28.2	 	Any annual cash bonus that the Executive shall become entitled to receive
hereunder for any calendar year shall be paid by the Company at such time and in such manner
that annual bonuses are paid to other senior executives of the Company, but not later than the
March 15 immediately following the end of the applicable calendar year; provided it shall not
be a breach of this Agreement if payment is made later in the year to the extent the bonus is
not determinable by March 15 and payment is made by payroll no later than December 31 of such
year.
	 
	28.3	 	Notwithstanding any provision in this Agreement to the contrary, to the extent
that any right to reimbursement of expenses under this Agreement constitutes “deferred
compensation” subject to Section 409A of the Code (“409A Deferred Compensation”), (i) the
expenses eligible for reimbursement or in-kind benefits provided to Executive must be incurred
during the Term, (ii) the amount of expenses eligible for reimbursement or in-kind benefits
provided to Executive during any calendar year will not affect the amount of expenses eligible
for reimbursement or in-kind benefits provided to Executive in any other calendar year, (iii)
the reimbursements for expenses for which Executive is entitled to be reimbursed shall be made
as soon as practicable but in no event later than the last day of the taxable year following
the taxable year in which the applicable expense is incurred by the Executive, provided that
the Executive has first properly submitted an expense report justifying those business costs,
and (iv) the right to payment or reimbursement or in-kind benefits hereunder may not be
liquidated or exchanged for any other benefit.
	 
	28.4	 	All payments to be made upon a termination of Employment under the Agreement will
only be made upon a “separation from service” under Section 409A of the Code. In no event may
the Executive, directly or indirectly, designate the calendar year of payment. To the maximum
extent permitted under Section 409A of the Code and its corresponding regulations, the amounts
payable under the Agreement to be made upon termination of Employment are intended to meet the
requirements of the short-term deferral exemption under Section 409A of the Code and the
“separation pay exception” under Treas. Reg. §1.409A-1(b)(9)(iii). For purposes of the
application of Treas. Reg. §1.409A-1(b)(4) (or any successor provision), each payment in a
series of payments to the Executive will be deemed a separate payment.





 - 14 - 









 






	28.5	 	Notwithstanding anything in this Agreement to the contrary, in the event that the
Executive is deemed to be a “specified employee” within the meaning of Section
409A(a)(2)(B)(i) of the Code, any payment under this Agreement that constitutes 409A Deferred
Compensation and would otherwise commence to be paid as a result of the Executive’s
“separation from service” (as defined in Section 409A of the Code and any Treasury Regulations
promulgated thereunder), will not be made to the Executive before the lapse of six months
after the date such payment would have been made but for this Section 29.5. Any payments of
accumulated 409A Deferred Compensation that are postponed in accordance with this Section 29.5
shall be paid in a lump sum payment within 10 days after the end of the six month period. If
the Executive dies during the postponement period prior to payment of the postponed amount,
the amounts withheld on account of Section 409A of the Code shall be paid to the personal
representative of the Executive’s estate within 60 days after the date of Executive’s death.
	 
	29	 	Governing Law
	 
	 	 	This Agreement shall be deemed a contract made under, and for all purposes shall be
construed in accordance with, the laws of the Commonwealth of Pennsylvania. Each of the
parties submits to the exclusive jurisdiction of the Commonwealth of Pennsylvania’s courts
as regards any claim or matter under this Agreement.
	 
	30	 	Titles
	 
	 	 	Titles to the Sections in this Agreement are intended solely for convenience and no
provision of this Agreement is to be construed by reference to the title of any Section.
	 
	 	 	In witness whereof the parties hereto have executed this Agreement as a deed on the day and
year first above written





	 	 	 	 	 

	GLAXOSMITHKLINE LLC	 	 
	 
	 	 	 	 
	By: 

Name:

	 	/s/ Justin Huang
 

Justin T Huang
	 	 
	Title:

	 	Assistant Secretary	 	 
	Date:

	 	12/21/10	 	 






	 	 	 	 	 

	Signed Sealed and Delivered by the
 said MONCEF
SLAOUI in the presence 

of:

	}
	/s/ Moncef Slaoui
 

	 	 
	 
	 	 	 	 
	Name: Raffaela Addis

	 	/s/ Raffaela Addis 
	 	 
	 

	 	 

	 	 
	Address:
	 	 	 	 
	 
	 	 	 	 
	Occupation Senior Executive Assistant
	 	 	 	 






 - 15 - 









 






Appendix 1: Schedule of Directorships and Outside Interests 



A list of the directorships and outside interests of the Executive approved by the GSK Board
as at the date of this Agreement is set out below:




	 	 	 

	Company Name

	 	Title






 - 16 - 









 






Appendix 2: Other Benefits



TotalReward makes the spirit of GSK an everyday reality for our people and is a major building
block for achieving our mission. The principles have been developed to ensure that the interest of
our employees is very closely aligned with GSK’s.



TotalReward is a competitive package designed to attract, retain, motivate and develop the best
talent. At the same time, it is cost-effective, benefiting GSK and our employees. Below is a list
providing examples of the benefits currently provided as at the date of the contract.



TotalReward includes:



Total Cash opportunities — Salary, Bonus, Deferred Annual Bonus Plan, Performance Share Plan



Long term savings and retirement plans — Cash Balance Pension Plan, Supplemental Cash Balance
Pension Plan, Retirement Savings Plan, Executive Supplemental Savings Plan (ESSP)



An array of comprehensive benefits to protect your health and welfare programs to help you better
balance your work life and your personal life — Executive Life Insurance Plan, Executive Medical
Plan, Retiree Medical Plan.



The Executive’s future participation in certain of these plans and programmes may be affected if he
does not satisfy the Share Ownership Requirements (as amended from time to time).



Details of the relevant plans and programmes and Share Ownership Requirements are set out in the
TotalReward section on connectGSK.



The Company reserves the right to amend, modify or withdraw the benefits, from time to time.





 - 17 -